Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank Disease ID
1 PARP1 [2] NF-kappa B signaling pathway, Necroptosis D09730 Olaparib [2] 86, 285
2 IFNA1 [7] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09662 Rontalizumab [1] 49
3 IFNA1 [7] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09668 Sifalimumab [1] 49
4 IFNA2 [7] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09662 Rontalizumab [1] 49
5 IFNA2 [7] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09668 Sifalimumab [1] 49
6 IFNA4 [7] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09662 Rontalizumab [1] 49
7 IFNA4 [7] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09668 Sifalimumab [1] 49
8 IFNA5 [7] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09662 Rontalizumab [1] 49
9 IFNA5 [7] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09668 Sifalimumab [1] 49
10 IFNA6 [7] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09662 Rontalizumab [1] 49
11 IFNA6 [7] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09668 Sifalimumab [1] 49
12 IFNA7 [7] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09662 Rontalizumab [1] 49
13 IFNA7 [7] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09668 Sifalimumab [1] 49
14 IFNA8 [7] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09662 Rontalizumab [1] 49
15 IFNA8 [7] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09668 Sifalimumab [1] 49
16 IFNA10 [7] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09662 Rontalizumab [1] 49
17 IFNA10 [7] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09668 Sifalimumab [1] 49
18 IFNA13 [7] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09662 Rontalizumab [1] 49
19 IFNA13 [7] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09668 Sifalimumab [1] 49
20 IFNA14 [7] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09662 Rontalizumab [1] 49
21 IFNA14 [7] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09668 Sifalimumab [1] 49
22 IFNA16 [7] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09662 Rontalizumab [1] 49
23 IFNA16 [7] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09668 Sifalimumab [1] 49
24 IFNA17 [7] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09662 Rontalizumab [1] 49
25 IFNA17 [7] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09668 Sifalimumab [1] 49
26 IFNA21 [7] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09662 Rontalizumab [1] 49
27 IFNA21 [7] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer D09668 Sifalimumab [1] 49
28 IFNAR1 [6] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer D00745 Interferon alfa-2a [1] 56
29 IFNAR1 [6] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer D00746 Interferon beta-1b [1] 13
30 IFNAR1 [6] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer D02745 Interferon alfa-2b [2] 25, 34
31 IFNAR1 [6] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer D03305 Interferon alfa [6] 13, 25, 26, 28, 56, 96
32 IFNAR1 [6] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer D04554 Interferon beta-1a [4] 13, 26, 96, 97
33 IFNAR1 [6] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer D10483 Peginterferon beta-1a [1] 13
34 IFNAR1 [6] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer D11082 Anifrolumab [3] 46, 49, 53
35 IFNAR2 [6] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer D00745 Interferon alfa-2a [1] 56
36 IFNAR2 [6] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer D00746 Interferon beta-1b [1] 13
37 IFNAR2 [6] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer D02745 Interferon alfa-2b [2] 25, 34
38 IFNAR2 [6] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer D03305 Interferon alfa [6] 13, 25, 26, 28, 56, 96
39 IFNAR2 [6] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer D04554 Interferon beta-1a [4] 13, 26, 96, 97
40 IFNAR2 [6] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer D10483 Peginterferon beta-1a [1] 13
41 IFNAR2 [6] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer D11082 Anifrolumab [3] 46, 49, 53
42 IFNG [14] Proteasome, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Type I diabetes mellitus, Toxoplasmosis, Tuberculosis, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D04242 Fontolizumab [1] 46
43 IFNG [14] Proteasome, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Type I diabetes mellitus, Toxoplasmosis, Tuberculosis, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D11120 Emapalumab [3] 49, 65, 107
44 IFNGR1 [8] Necroptosis, Osteoclast differentiation, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D00747 Interferon gamma-1b [7] 18, 65, 85, 228, 299, 301, 326
45 IFNGR2 [8] Necroptosis, Osteoclast differentiation, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D00747 Interferon gamma-1b [7] 18, 65, 85, 228, 299, 301, 326
46 IL1A [9] Necroptosis, Osteoclast differentiation, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Tuberculosis, Rheumatoid arthritis D01583 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
47 IL1A [9] Necroptosis, Osteoclast differentiation, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Tuberculosis, Rheumatoid arthritis D06635 Rilonacept [4] 51, 106, 107, 266
48 IL1A [9] Necroptosis, Osteoclast differentiation, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Tuberculosis, Rheumatoid arthritis D11253 Bermekimab [1] 51
49 IL1B [18] NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Rheumatoid arthritis D01583 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
50 IL1B [18] NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Rheumatoid arthritis D06635 Rilonacept [4] 51, 106, 107, 266
51 IL1B [18] NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Rheumatoid arthritis D09315 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269
52 IL1B [18] NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Rheumatoid arthritis D09911 Gevokizumab [4] 41, 50, 56, 269
53 JAK1 [13] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09959 Ruxolitinib [3] 60, 65, 228
54 JAK1 [13] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09970 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300
55 JAK1 [13] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10308 Baricitinib [13] 2, 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325
56 JAK1 [13] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10653 Peficitinib [1] 46
57 JAK1 [13] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10871 Filgotinib [6] 46, 53, 96, 97, 222, 271
58 JAK1 [13] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10944 Itacitinib [4] 46, 51, 97, 228
59 JAK1 [13] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10994 Upadacitinib [8] 40, 41, 46, 49, 96, 97, 107, 271
60 JAK1 [13] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D11400 Abrocitinib [1] 84
61 JAK2 [10] PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Prolactin signaling pathway, Toxoplasmosis, Tuberculosis, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09959 Ruxolitinib [3] 60, 65, 228
62 JAK2 [10] PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Prolactin signaling pathway, Toxoplasmosis, Tuberculosis, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09970 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300
63 JAK2 [10] PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Prolactin signaling pathway, Toxoplasmosis, Tuberculosis, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10308 Baricitinib [13] 2, 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325
64 JAK2 [10] PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Prolactin signaling pathway, Toxoplasmosis, Tuberculosis, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10653 Peficitinib [1] 46
65 JAK3 [9] PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Pathways in cancer, Viral carcinogenesis, Non-small cell lung cancer, Primary immunodeficiency D09970 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300
66 JAK3 [9] PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Pathways in cancer, Viral carcinogenesis, Non-small cell lung cancer, Primary immunodeficiency D10653 Peficitinib [1] 46
67 BCL2 [18] Platinum drug resistance, NF-kappa B signaling pathway, Sphingolipid signaling pathway, p53 signaling pathway, Protein processing in endoplasmic reticulum, PI3K-Akt signaling pathway, Necroptosis, NOD-like receptor signaling pathway, Neurotrophin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Shigellosis, Salmonella infection, Toxoplasmosis, Tuberculosis, Pathways in cancer, Prostate cancer, Small cell lung cancer D10679 Venetoclax [1] 28
68 SMPD1 [3] Sphingolipid metabolism, Sphingolipid signaling pathway, Necroptosis D10820 Olipudase alfa [1] 19
69 TNF [26] Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D00742 Etanercept [16] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 107, 228, 270, 271, 285
70 TNF [26] Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D00754 Thalidomide [20] 2, 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331
71 TNF [26] Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D01583 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
72 TNF [26] Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D02597 Adalimumab [17] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271
73 TNF [26] Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D02598 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271
74 TNF [26] Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D03441 Certolizumab pegol [8] 37, 46, 49, 96, 97, 107, 226, 271
75 TNF [26] Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D04358 Golimumab [8] 46, 56, 84, 96, 97, 107, 270, 271
76 TNF [26] Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D04687 Lenalidomide [8] 16, 26, 28, 34, 49, 284, 300, 331
77 TNF [26] Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D05393 Pegsunercept [1] 46
78 TNF [26] Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D08976 Pomalidomide [5] 28, 51, 85, 227, 331
79 TNF [26] Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D09944 Ozoralizumab [1] 46
80 TYK2 [6] Necroptosis, Osteoclast differentiation, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis D09970 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300
81 TYK2 [6] Necroptosis, Osteoclast differentiation, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis D11817 Deucravacitinib [3] 49, 96, 97